| Dr Powen Hsu, MD | |
|
280 Pleasant St Ste 1, Concord, NH 03301-2553 | |
| (603) 622-8665 | |
| (833) 413-4978 |
| Full Name | Dr Powen Hsu |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 37 Years |
| Location | 280 Pleasant St Ste 1, Concord, New Hampshire |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912991159 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 8900 (New Hampshire) | Primary |
| 207QA0401X | Family Medicine - Addiction Medicine | 8900 (New Hampshire) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vna Home Health And Hospice Services, Inc | Manchester, NH | Home health agency |
| Concord Hospital | Concord, NH | Hospital |
| Elliot Hospital | Manchester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Derry Medical Center, Pa | 5294711768 | 58 |
| Riverbend Community Mental Health, Inc | 6103815584 | 43 |
| Fusion Health Services Llc | 6608111273 | 5 |
News Archive
WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to the emergence of H1N1 (swine flu), the Associated Press reports. According to Fukuda, the committee will hold its first meeting April 12-14 (3/29).
The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.
The administration credits the significant savings to changes in the Medicare program that were put in place by the health law combined with other steps to cut down on fraud and abuse, quality of care incentives, and efforts to streamline care for people with disabilities.
NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.
› Verified 9 days ago
| Entity Name | New Era Medicine Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568584407 PECOS PAC ID: 6204730740 Enrollment ID: O20031125000690 |
News Archive
WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to the emergence of H1N1 (swine flu), the Associated Press reports. According to Fukuda, the committee will hold its first meeting April 12-14 (3/29).
The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.
The administration credits the significant savings to changes in the Medicare program that were put in place by the health law combined with other steps to cut down on fraud and abuse, quality of care incentives, and efforts to streamline care for people with disabilities.
NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.
› Verified 9 days ago
| Entity Name | Riverbend Community Mental Health, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942264940 PECOS PAC ID: 6103815584 Enrollment ID: O20040511000152 |
News Archive
WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to the emergence of H1N1 (swine flu), the Associated Press reports. According to Fukuda, the committee will hold its first meeting April 12-14 (3/29).
The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.
The administration credits the significant savings to changes in the Medicare program that were put in place by the health law combined with other steps to cut down on fraud and abuse, quality of care incentives, and efforts to streamline care for people with disabilities.
NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.
› Verified 9 days ago
| Entity Name | Derry Medical Center, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922030493 PECOS PAC ID: 5294711768 Enrollment ID: O20040625000380 |
News Archive
WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to the emergence of H1N1 (swine flu), the Associated Press reports. According to Fukuda, the committee will hold its first meeting April 12-14 (3/29).
The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.
The administration credits the significant savings to changes in the Medicare program that were put in place by the health law combined with other steps to cut down on fraud and abuse, quality of care incentives, and efforts to streamline care for people with disabilities.
NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.
› Verified 9 days ago
| Entity Name | Catholic Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427154335 PECOS PAC ID: 6103897129 Enrollment ID: O20040803001720 |
News Archive
WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to the emergence of H1N1 (swine flu), the Associated Press reports. According to Fukuda, the committee will hold its first meeting April 12-14 (3/29).
The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.
The administration credits the significant savings to changes in the Medicare program that were put in place by the health law combined with other steps to cut down on fraud and abuse, quality of care incentives, and efforts to streamline care for people with disabilities.
NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.
› Verified 9 days ago
| Entity Name | Crotched Mountain Rehabilitation Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891721262 PECOS PAC ID: 5597731059 Enrollment ID: O20040907000356 |
News Archive
WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to the emergence of H1N1 (swine flu), the Associated Press reports. According to Fukuda, the committee will hold its first meeting April 12-14 (3/29).
The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.
The administration credits the significant savings to changes in the Medicare program that were put in place by the health law combined with other steps to cut down on fraud and abuse, quality of care incentives, and efforts to streamline care for people with disabilities.
NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.
› Verified 9 days ago
| Entity Name | Alice Peck Day Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003803495 PECOS PAC ID: 6103737531 Enrollment ID: O20040927000296 |
News Archive
WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to the emergence of H1N1 (swine flu), the Associated Press reports. According to Fukuda, the committee will hold its first meeting April 12-14 (3/29).
The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.
The administration credits the significant savings to changes in the Medicare program that were put in place by the health law combined with other steps to cut down on fraud and abuse, quality of care incentives, and efforts to streamline care for people with disabilities.
NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.
› Verified 9 days ago
| Entity Name | Catholic Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336245240 PECOS PAC ID: 6103897129 Enrollment ID: O20041022000879 |
News Archive
WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to the emergence of H1N1 (swine flu), the Associated Press reports. According to Fukuda, the committee will hold its first meeting April 12-14 (3/29).
The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.
The administration credits the significant savings to changes in the Medicare program that were put in place by the health law combined with other steps to cut down on fraud and abuse, quality of care incentives, and efforts to streamline care for people with disabilities.
NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.
› Verified 9 days ago
| Entity Name | Manchester Alcoholism Rehabilitation Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720151830 PECOS PAC ID: 8527368612 Enrollment ID: O20151120001905 |
News Archive
WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to the emergence of H1N1 (swine flu), the Associated Press reports. According to Fukuda, the committee will hold its first meeting April 12-14 (3/29).
The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.
The administration credits the significant savings to changes in the Medicare program that were put in place by the health law combined with other steps to cut down on fraud and abuse, quality of care incentives, and efforts to streamline care for people with disabilities.
NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.
› Verified 9 days ago
| Entity Name | Fusion Health Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750889747 PECOS PAC ID: 6608111273 Enrollment ID: O20181231001427 |
News Archive
WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to the emergence of H1N1 (swine flu), the Associated Press reports. According to Fukuda, the committee will hold its first meeting April 12-14 (3/29).
The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.
The administration credits the significant savings to changes in the Medicare program that were put in place by the health law combined with other steps to cut down on fraud and abuse, quality of care incentives, and efforts to streamline care for people with disabilities.
NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Powen Hsu, MD 280 Pleasant St Ste 1, Concord, NH 03301-2553 Ph: (603) 622-8665 | Dr Powen Hsu, MD 280 Pleasant St Ste 1, Concord, NH 03301-2553 Ph: (603) 622-8665 |
News Archive
WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to the emergence of H1N1 (swine flu), the Associated Press reports. According to Fukuda, the committee will hold its first meeting April 12-14 (3/29).
The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.
The administration credits the significant savings to changes in the Medicare program that were put in place by the health law combined with other steps to cut down on fraud and abuse, quality of care incentives, and efforts to streamline care for people with disabilities.
NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.
› Verified 9 days ago
Dr. Jung-woo Ma, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 264 Pleasant St, Concord, NH 03301 Phone: 603-224-3368 Fax: 603-224-7815 | |
Martha S Torrey, PT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 28 Commercial Street, Concord, NH 03301 Phone: 603-225-5132 Fax: 603-225-6061 | |
Jessica L Mack, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 264 Pleasant St, Concord, NH 03301 Phone: 603-224-3368 Fax: 603-224-7815 | |
Carolanne L Wong, PT Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 28 Commercial St, Concord, NH 03301 Phone: 603-225-5132 Fax: 603-225-6061 | |
Margaret M Donohue, PT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 28 Commerical St, Concord, NH 03301 Phone: 603-225-5132 Fax: 603-225-6061 | |
Ms. Joanne Marie Mclean, PT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 28 Commerce Street, Concord, NH 03301 Phone: 603-225-5132 Fax: 603-225-6061 | |
Jeffrey T Clough, PT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 28 Commerical St, Concord, NH 03301 Phone: 603-225-5132 Fax: 603-225-6061 |